- Home
- EBS vs PGEN Comparison
EBS vs PGEN Comparison
Compare EBS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- PGEN
- Stock Information
- Founded
- EBS 1998
- PGEN 1998
- Country
- EBS United States
- PGEN United States
- Employees
- EBS N/A
- PGEN N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- PGEN Health Care
- Exchange
- EBS Nasdaq
- PGEN Nasdaq
- Market Cap
- EBS 393.9M
- PGEN 344.0M
- IPO Year
- EBS 2006
- PGEN N/A
- Fundamental
- Price
- EBS $5.04
- PGEN $1.59
- Analyst Decision
- EBS Strong Buy
- PGEN Strong Buy
- Analyst Count
- EBS 3
- PGEN 4
- Target Price
- EBS $14.33
- PGEN $7.33
- AVG Volume (30 Days)
- EBS 1.2M
- PGEN 1.4M
- Earning Date
- EBS 05-07-2025
- PGEN 05-13-2025
- Dividend Yield
- EBS N/A
- PGEN N/A
- EPS Growth
- EBS N/A
- PGEN N/A
- EPS
- EBS N/A
- PGEN N/A
- Revenue
- EBS $1,043,600,000.00
- PGEN $3,925,000.00
- Revenue This Year
- EBS N/A
- PGEN $189.12
- Revenue Next Year
- EBS $19.88
- PGEN $1,093.07
- P/E Ratio
- EBS N/A
- PGEN N/A
- Revenue Growth
- EBS N/A
- PGEN N/A
- 52 Week Low
- EBS $1.82
- PGEN $0.65
- 52 Week High
- EBS $15.10
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- EBS 48.72
- PGEN 54.87
- Support Level
- EBS $4.13
- PGEN $1.33
- Resistance Level
- EBS $4.69
- PGEN $1.49
- Average True Range (ATR)
- EBS 0.35
- PGEN 0.14
- MACD
- EBS 0.15
- PGEN 0.03
- Stochastic Oscillator
- EBS 94.91
- PGEN 92.33
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.